Literature DB >> 9399979

Active immunization alters the plasma nicotine concentration in rats.

Y Hieda1, D E Keyler, J T Vandevoort, J K Kane, C A Ross, D E Raphael, R S Niedbalas, P R Pentel.   

Abstract

The ability of active immunization to alter nicotine distribution was studied in rats. Animals were immunized with 6-(carboxymethylureido)-(+/-)-nicotine (CMUNic) linked to keyhole limpet hemocyanin (KLH). Antibody titers determined by ELISA, using CMUNic coupled to albumin as the coating antigen, were greater than 1:10,000. Antibody binding was inhibited by neither of the nicotine metabolites cotinine and nicotine-N-oxide but was inhibited to a greater extent by CMUNic than by nicotine; this suggests the presence of antibodies to the linker structure as well as antibodies to nicotine. Antibody affinity for nicotine measured by soluble radioimmunoassay was 2.4 +/- 1.6 x 10(7) M-1, and binding capacity was 1.3 +/- 0.7 x 10(-6) M, which corresponds to 0.1 +/- 0.05 mg/ml of nicotine-specific IgG per milliliter of serum. One week after their second boost, groups of eight anesthetized rats immunized with either CMUNic-KLH or KLH alone received nicotine 0.03 mg/kg (equivalent to two cigarettes in a human) via the jugular vein over 10 sec. This dosing regimen was shown to mimic the arterio-venous nicotine concentration gradient typical of nicotine delivered by cigarette smoking in humans. Plasma nicotine concentrations at 10 to 40 min were 4 to 6-fold higher in the CMUNic-KLH rats than in controls (P < .001). Nicotine binding in plasma determined by equilibrium dialysis was markedly increased in the CMUNic-KLH group (83.4 +/- 6.8% vs. 16.4 +/- 14.2%), but brain nicotine concentrations at 40 min did not differ (37.9 +/- 4.5 vs. 44.0 +/- 8. 4 ng/g, CMUNic-KLH vs. KLH, P = .1). The amount of nicotine bound to antibody in plasma, estimated from the in vivo data, was 9% of the administered dose. These data demonstrate that active immunization can bind a significant fraction of a clinically relevant nicotine dose in plasma. Observing this effect with antibodies of modest affinity and titer is encouraging, but better immunogens may be needed to alter nicotine distribution to brain and modify nicotine's behavioral effects.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9399979

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  31 in total

Review 1.  Vaccines against nicotine: how effective are they likely to be in preventing smoking?

Authors:  F J Vocci; C N Chiang
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

2.  Active immunization against nicotine alters the distribution of nicotine but not the metabolism to cotinine in the rat.

Authors:  Sabina H L de Villiers; Nina Lindblom; Genadiy Kalayanov; Sandra Gordon; Anette M Johansson; Torgny H Svensson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-09-16       Impact factor: 3.000

Review 3.  Current status of immunologic approaches to treating tobacco dependence: vaccines and nicotine-specific antibodies.

Authors:  Mark G LeSage; Daniel E Keyler; Paul R Pentel
Journal:  AAPS J       Date:  2006-02-24       Impact factor: 4.009

4.  Increased efficacy of a trivalent nicotine vaccine compared to a dose-matched monovalent vaccine when formulated with alum.

Authors:  Sabina H L de Villiers; Katherine E Cornish; Andrew J Troska; Marco Pravetoni; Paul R Pentel
Journal:  Vaccine       Date:  2013-10-29       Impact factor: 3.641

Review 5.  Conjugate Vaccine Immunotherapy for Substance Use Disorder.

Authors:  Paul T Bremer; Kim D Janda
Journal:  Pharmacol Rev       Date:  2017-07       Impact factor: 25.468

6.  An oxycodone conjugate vaccine elicits drug-specific antibodies that reduce oxycodone distribution to brain and hot-plate analgesia.

Authors:  M Pravetoni; M Le Naour; T M Harmon; A M Tucker; P S Portoghese; P R Pentel
Journal:  J Pharmacol Exp Ther       Date:  2012-01-18       Impact factor: 4.030

7.  A nanoparticle-based nicotine vaccine and the influence of particle size on its immunogenicity and efficacy.

Authors:  Zongmin Zhao; Yun Hu; Reece Hoerle; Meaghan Devine; Michael Raleigh; Paul Pentel; Chenming Zhang
Journal:  Nanomedicine       Date:  2016-08-09       Impact factor: 5.307

Review 8.  Prospects, promise and problems on the road to effective vaccines and related therapies for substance abuse.

Authors:  Stephen Brimijoin; Xiaoyun Shen; Frank Orson; Thomas Kosten
Journal:  Expert Rev Vaccines       Date:  2013-03       Impact factor: 5.217

Review 9.  Substance abuse vaccines.

Authors:  Frank M Orson; Berma M Kinsey; Rana A K Singh; Yan Wu; Tracie Gardner; Thomas R Kosten
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

Review 10.  Immunopharmacotherapy: vaccination strategies as a treatment for drug abuse and dependence.

Authors:  Amira Y Moreno; Kim D Janda
Journal:  Pharmacol Biochem Behav       Date:  2009-04       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.